8 citations
,
January 2019 in “Clinical research and trials” This study found that long-term treatment with 1 mg/day finasteride over 10 years resulted in high efficacy and prevention of disease progression in Japanese men with androgenetic alopecia, with no serious adverse reactions reported.
32 citations
,
July 2020 in “Journal of The American Academy of Dermatology” This study noted that among hospitalized COVID-19 patients, androgenetic alopecia was prevalent, and severe cases were associated with adverse outcomes such as respiratory failure, highlighting a possible link with androgen sensitivity.
29 citations
,
July 2020 in “Journal of The American Academy of Dermatology” In this study, researchers found that severe androgenic alopecia in hospitalized men was associated with a higher likelihood of testing positive for COVID-19.
6 citations
,
September 2020 in “Journal of The American Academy of Dermatology” This letter discusses how severe baldness in men is associated with higher risk of severe COVID-19, and highlights research suggesting antiandrogen medications may improve outcomes.
2 citations
,
August 2020 in “Journal of The American Academy of Dermatology” This letter discusses existing research and encourages further studies on the relationship between androgenetic alopecia and COVID-19 severity, reporting no new clinical results.